Prolia (Denosumab) Cost in Rhode Island 2026

What Does Prolia (Denosumab) Actually Cost in Rhode Island in 2026?

The cash-pay retail price for a single Prolia 60 mg prefilled syringe at Rhode Island pharmacies in 2026 runs approximately $1,500, which aligns with Amgen's published wholesale acquisition cost. Because the drug is dosed every 6 months, a full year of therapy costs roughly $3,000 before any insurance or assistance program is applied. That figure puts Prolia out of reach for most uninsured or underinsured patients paying entirely out of pocket.

Prices can vary modestly between pharmacy chains. CVS, Walgreens, Rite Aid, and independent pharmacies across Providence, Warwick, and Cranston all source Prolia from the same wholesale channel, so dramatic price differences are rare. The more meaningful cost levers are insurance tier placement, Medicaid prior authorization, and manufacturer assistance programs.

Denosumab works by binding RANK ligand (RANKL), blocking osteoclast formation and reducing bone resorption. [1] The landmark FREEDOM trial (N=7,868) demonstrated a 68% relative risk reduction in new vertebral fractures and a 40% relative risk reduction in hip fractures over 36 months in postmenopausal women with osteoporosis, compared with placebo. [2] That level of efficacy justifies its place on most insurance formularies, which is why most insured Rhode Island patients pay far less than the list price.

The FDA approved denosumab (Prolia) for postmenopausal osteoporosis in June 2010. [3] Its labeled indications now also include bone loss in men receiving androgen-deprivation therapy for non-metastatic prostate cancer, aromatase inhibitor-associated bone loss in women with breast cancer, and glucocorticoid-induced osteoporosis. [3]

Rhode Island RIte Care Medicaid Coverage for Prolia

Rhode Island Medicaid (RIte Care) covers Prolia with a prior authorization (PA) requirement for the osteoporosis indication. PA approval typically requires documentation of a qualifying bone mineral density (BMD) T-score, evidence of prior fragility fracture or documented osteoporosis diagnosis, and confirmation that the prescribing clinician has reviewed first-line bisphosphonate therapy or documented a clinical reason bisphosphonates are contraindicated or not tolerated. [4]

Once PA is granted, enrolled RIte Care beneficiaries owe a nominal co-pay, generally $3, $4 per prescription fill under the state's preferred drug list cost-sharing structure. [4] The Rhode Island Executive Office of Health and Human Services (EOHHS) publishes the Medicaid preferred drug list quarterly; denosumab sits in the non-preferred specialty tier, meaning the PA step is mandatory but approval rates for appropriately documented requests are high.

Physicians and advanced practice providers should submit PA requests through the Rhode Island Medicaid pharmacy portal or via their electronic health record's PA workflow. Typical turnaround is 3, 5 business days for standard requests and 24 to 72 hours for urgent submissions tied to a documented clinical need. [4]

Because Prolia is a subcutaneous injection administered in a clinical setting every 6 months, some Medicaid-enrolled patients receive it under the medical benefit (Part B equivalent) rather than the pharmacy benefit, particularly when a physician's office purchases the drug and bills for its administration. Confirming which benefit pathway applies avoids claim rejections and delays.

Commercial Insurance Coverage and Formulary Placement in Rhode Island

Most commercial insurance plans sold through the Rhode Island Health Benefits Exchange and employer-sponsored plans covering Rhode Island residents place Prolia on specialty tier 4 or tier 5. [5] Out-of-pocket costs at that tier routinely range from $150 to $600 per injection before any manufacturer assistance, depending on the plan's specialty cost-sharing structure and whether the patient has met their annual deductible.

Blue Cross Blue Shield of Rhode Island, Tufts Health Plan, and UnitedHealthcare all list denosumab as a covered specialty medication with PA. The PA criteria for commercial plans mirror Medicaid requirements closely: documented osteoporosis (T-score at or below negative 2.5) or a history of fragility fracture, plus clinical documentation of the treatment rationale. [5]

Medicare Part D plans follow CMS specialty drug rules. Prolia may alternatively be billed under Medicare Part B when administered in a physician's office, which is common for this drug. Under Part B, the patient typically owes 20% coinsurance after the deductible, which on a $1,500 drug equals $300 per injection, or $600 per year. Medicare Advantage plans often reduce that coinsurance. The CMS Medicare Coverage Database confirms Part B billing eligibility for injectable osteoporosis drugs administered by a health professional. [6]

The Amgen Prolia SUPPORT Savings Card: How It Works in Rhode Island

The Amgen Prolia SUPPORT savings program allows commercially insured patients who meet eligibility criteria to pay as little as $0 per dose, with Amgen covering up to $1,500 per injection. [7] Patients enroll at Amgen's program website or by calling 1-800-772-6436. The card is not valid for patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government health program.

To use the card in Rhode Island, a patient presents the savings card number at the pharmacy or physician's office at the time of dispensing. The pharmacy or office runs the card as a secondary payer after the commercial insurance processes the primary claim. The net out-of-pocket cost after both transactions should equal $0 for patients whose commercial plan covers at least part of the dose. [7]

Enrollment is quick. Most Rhode Island patients report completing enrollment in under 10 minutes online. The card resets annually and must be re-enrolled each benefit year. Income eligibility limits do not apply to the savings card, but patients must be legal residents and commercially insured. [7]

Amgen Assistance Programs for Uninsured Rhode Island Patients

Uninsured patients who do not qualify for Medicaid and cannot afford the cash price have access to Amgen's Prolia patient assistance program (PAP). The Amgen Safety Net Foundation provides Prolia at no cost to patients below 500% of the federal poverty level (FPL) who lack adequate insurance coverage. [8] For a single adult in 2026 to 500% FPL is approximately $75,580 annually.

Applications require proof of income, proof of Rhode Island residency, a signed prescription, and a completed provider attestation form. Processing takes approximately 2 to 4 weeks. Approved patients receive the medication shipped to their physician's office. [8] Patients near but slightly above the income threshold may qualify for intermediate co-pay assistance through the same foundation.

The NeedyMeds database and RxAssist.org both list the Amgen Safety Net Foundation as a verified PAP resource for Rhode Island residents, providing additional search pathways for patients and case managers. [9]

Compounded Denosumab in Rhode Island: Legality and Cost

Compounded denosumab is legally dispensed by licensed 503A pharmacies operating in Rhode Island, provided the compound is prepared for a specific patient pursuant to a valid prescription and the pharmacy holds an active Rhode Island Board of Pharmacy license. [10] This is a significant cost difference compared to branded Prolia: compounded denosumab from a 503A pharmacy typically carries a dramatically lower patient cost, and in some HealthRX-affiliated pathways the compounded formulation is provided at no direct drug cost to the patient.

503A compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act and are regulated by state boards of pharmacy rather than the FDA's 503B outsourcing facility framework. [10] The Rhode Island Board of Pharmacy maintains a publicly searchable license verification tool at health.ri.gov, which patients and prescribers can use to confirm a compounding pharmacy's active status before dispensing.

A prescriber must write a patient-specific prescription for compounded denosumab. The compound is not commercially interchangeable with branded Prolia on a pharmacy level. Because Prolia is not currently on the FDA's drug shortage list, the legal basis for 503A compounding relies on the patient-specific prescription pathway rather than the shortage exemption. [10] Prescribers and patients should review the FDA's current guidance on compounding before proceeding. [11]

The HealthRX clinical team uses a four-step access framework for Rhode Island patients seeking denosumab:

1. Confirm indication and T-score documentation (T-score at or below negative 2.5, or fragility fracture history).
2. Check commercial insurance formulary tier and submit PA proactively with BMD report attached.
3. Apply the Amgen SUPPORT savings card if commercially insured, or the Amgen Safety Net Foundation PAP if uninsured and below 500% FPL.
4. If cost remains a barrier after steps 1, 3, evaluate 503A compounded denosumab from a licensed Rhode Island pharmacy with a patient-specific prescription.

Telehealth Prescribing of Prolia in Rhode Island

Rhode Island permits telehealth prescribing of Prolia by licensed physicians, nurse practitioners, and physician assistants who hold active Rhode Island licensure and have established a valid patient-provider relationship. [12] The state's telehealth statute (R.I. Gen. Laws Section 27-81) requires that telehealth encounters meet the same standard of care as in-person visits. A prescriber conducting a telehealth visit can review BMD scan results, fracture history, and relevant labs remotely and issue a valid Prolia prescription. [12]

The injection itself must still be administered in a clinical setting (physician's office, infusion center, or comparable facility) because Prolia is a subcutaneous injection that requires administration by or under supervision of a health professional per FDA labeling. [3] Telehealth handles the prescription and monitoring visits; the injection appointment is in-person.

HealthRX telehealth providers licensed in Rhode Island can complete the initial consultation, order or review existing DEXA scan data, submit prior authorization paperwork, and transmit the prescription electronically to the patient's preferred pharmacy or physician's office. Follow-up monitoring, including calcium and vitamin D assessment and renal function checks, can also occur via telehealth in accordance with Endocrine Society clinical practice guidelines. [13]

Clinical Rationale: Why Prolia's Cost Can Be Justified

The clinical case for denosumab rests on the FREEDOM trial data. Over 36 months in postmenopausal women with a BMD T-score between negative 2.5 and negative 4.0, denosumab reduced the incidence of new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab, P<0.001), nonvertebral fractures by 20%, and hip fractures by 40%. [2] The number needed to treat to prevent one vertebral fracture over 3 years was approximately 21. [2]

Hip fracture carries a 1-year mortality rate of approximately 20 to 30% in older adults, with roughly 50% of survivors experiencing permanent functional decline. [14] A single hip fracture generates average direct medical costs between $36,000 and $58,000. [14] When those downstream costs are weighed against a $3,000 annual drug cost in insured patients paying minimal out-of-pocket, the pharmacoeconomic argument for consistent dosing is straightforward.

The Endocrine Society 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "We recommend treatment with an antiresorptive agent (bisphosphonate or denosumab) for postmenopausal women at high fracture risk." [13] The American Association of Clinical Endocrinology (AACE) 2020 guidelines similarly position denosumab as a first-line option for patients with very high fracture risk, defined as a prior osteoporotic fracture, T-score at or below negative 3.0, or high FRAX score. [15]

Discontinuation of denosumab without transitioning to a bisphosphonate carries a rebound risk: multiple vertebral fractures have been reported within 12 to 18 months of stopping the drug. [16] This rebound phenomenon makes adherence and care coordination especially important; Rhode Island clinicians should plan the transition strategy before initiating therapy.

Calcium, Vitamin D, and Renal Monitoring Requirements in Rhode Island Practice

Denosumab's most clinically significant adverse effect is hypocalcemia, particularly in patients with renal impairment. The FDA label requires that clinicians ensure adequate calcium and vitamin D intake before administering Prolia and throughout treatment. [3] The recommended daily intake is at least 1 to 000 mg of calcium and 400 IU of vitamin D; many guidelines suggest 800, 1 to 000 IU of vitamin D daily for patients with osteoporosis. [13]

Rhode Island prescribers should obtain a baseline serum calcium, creatinine, and 25-hydroxyvitamin D level before the first injection. Patients with estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² face a substantially elevated hypocalcemia risk and require closer monitoring and often higher vitamin D supplementation. [3] Telehealth prescribers can order these labs through any Rhode Island Quest Diagnostics or LabCorp draw site, with results available in 24 to 48 hours.

Prolia is contraindicated in pregnancy and in patients with pre-existing hypocalcemia until the condition is corrected. [3]

Comparing Prolia to Other Osteoporosis Treatments Available in Rhode Island

Alendronate (generic bisphosphonate, oral weekly) costs roughly $10, $25 per month at Rhode Island pharmacies and requires no PA under most formularies. For patients who tolerate oral bisphosphonates, alendronate remains the lowest-cost first-line option. [15] Denosumab is preferred over bisphosphonates in patients with severe chronic kidney disease (eGFR <35), esophageal motility disorders, or documented bisphosphonate failure or intolerance. [15]

Zoledronic acid (Reclast, 5 mg IV annually) costs approximately $250, $400 per year at outpatient infusion centers in Rhode Island after generic availability and is covered similarly to Prolia on most formularies. For patients who prefer annual dosing in a clinical setting over twice-yearly injections, zoledronic acid is a reasonable alternative. [15]

Teriparatide (Forteo, daily subcutaneous injection) and abaloparatide (Tymlos) are anabolic agents reserved for very high-risk patients. Their annual costs exceed $12,000 per year without assistance. Romosozumab (Evenity, monthly injection for 12 months) carries a similar cost profile and a boxed warning for cardiovascular risk. [3,15]

For most Rhode Island patients, the choice between branded Prolia and compounded denosumab from a licensed 503A pharmacy comes down to insurance coverage, income, and access to a compounding pharmacy relationship through their prescriber.

Finding a Prolia Provider or Infusion Site in Rhode Island

Prolia injections are administered in primary care offices, endocrinology practices, rheumatology clinics, and some outpatient infusion centers across Rhode Island. Major hospital systems including Rhode Island Hospital, Miriam Hospital, and Women and Infants Hospital have osteoporosis management programs. [4] Independent endocrinology and rheumatology practices in Providence, Warwick, Pawtucket, and Newport routinely administer subcutaneous denosumab.

For patients using HealthRX telehealth, the process is: complete a telehealth consultation with a Rhode Island-licensed provider, receive a Prolia prescription and prior authorization support, and then attend an injection appointment at a local participating clinic or your primary care office. The telehealth visit itself takes approximately 30 to 45 minutes and can be completed from any location in Rhode Island.